Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Key Highlights
- ➤Q3 revenue expected $9.8M-$10.0M, above Wall Street expectations
- ➤Revenue expected up 85%-89% year over year from $5.3M
- ➤Revenue expected up 292%-300% sequentially from $2.5M
- ➤Q3 revenue expected 45%-47% above Bloomberg consensus of $6.78M
- ➤Q3 gross margin expected to exceed 70% again
Expert Statements
Arun Menawat, CEO and Chairman of Profound Medical
“The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building behind our technology.”
Arun Menawat, CEO and Chairman of Profound Medical
“The expected year-over-year and sequential growth in the third quarter reflects increased commercial activity across our installed base and new customer accounts.”
Arun Menawat, CEO and Chairman of Profound Medical
“With preliminary revenue of approximately $9.8 million to $10.0 million and gross margin expected to exceed 70%, we believe the third quarter represents an important step in the continued expansion of our commercial business.”
Arun Menawat, CEO and Chairman of Profound Medical
“We remain focused on supporting customer adoption, increasing utilization of our installed base, and building a profitable growth company over the long-term.”
TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced preliminary unaudited revenues for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars.
Based on these preliminary results, the Company expects to report record-breaking quarterly revenue that is above current Wall Street expectations.
Get started
Create a free account to read the full story.